(1 - 135)
1. Andreas S. Endocrinological derangement in COPD. Eur Respir J. 2010;35(4):933; author reply 4. PubMed PMID: 20356994.
2. Calverley P, Miserocchi G, Puente Maestu L, Aliverti A, De Backer W, Andreas S, et al. The changing face of respiratory physiology: 20 years of progress within the ERS: Clinical Physiology and Integrative Biology Assembly contribution to the celebration of 20 years of the ERS. Eur Respir J. 2010;35(5):945-8. PubMed PMID: 20436168.
3. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. Prävention, Diagnose, Therapie, and Nachsorge des Lungenkarzinoms. S3 LL. Pneumologie. 2010;64 Suppl 2:e1-164. PubMed PMID: 20217630.
4. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, et al. Nicht invasive Diagnostik der pulmonalen Hypertonie. ESC/ERS-Leitlinien mit Kommentierung der Kölner Konsensus Konferenz 2010. Dtsch Med Wochenschr. 2010;135 Suppl 3:S115-24. PubMed PMID: 20862620.
5. Jahne A, Cohrs S, Rodenbeck A, Andreas S, Loessl B, Feige B, et al. Nicotine : Influence on sleep and its relevance for psychiatry and psychotherapy. Der Nervenarzt. 2010;81:844-59. PubMed PMID: 20182857.
6. Raupach T, Bahr F, Herrmann P, Lüthje L, Hasenfuss G, Andreas S. Inspiratory resistive loading does not increase sympathetic tone in COPD. Respir Med. 2010;104(1):107-13. PubMed PMID: 19619996.
7. Raupach T, Shahab L, Eimer S, Puls M, Hasenfuss G, Andreas S. Increasing the use of nicotine replacement therapy by a simple intervention: an exploratory trial. Substance use & misuse. 2010;45(3):403-13. PubMed PMID: 20141455.
8. Andreas S. Beta blocker in COPD - precedents in heart failure. Brit Med j. 2011;342 rapid response.
9. Andreas S, Gamarra F, Herth F, Hoffmann H, Nowak D, Riha S, et al. Non Small Cell Lung Cancer - Prävention und Früherkennung Onkologie. 2011;34 Suppl 4:2-10. PubMed PMID: 21677467.
10. De Backer W, Simonds AK, Horn V, Andreas S, Bonsignore M, Calverley P, et al. Sleep HERMES: a European training project for respiratory sleep medicine. Eur Respir J. 2011;38(3):496-7. PubMed PMID: 21885409.
11. Floras J, Andreas S. Sleep apnoea and malignant ventricular arrhythmias in heart failure. Eur Heart J. 2011;32(1):10-2. PubMed PMID: 20929983.
12. Goeckenjan G, Sitter H, Thomas M, Branscheid D, Flentje M, Griesinger F, et al. Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version. Pneumologie. 2011;65(8):e51-75. PubMed PMID: 21830177.
13. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, et al. Pulmonary Hypertension Due to Chronic Lung Disease. Pneumologie. 2011;65(4):208-18. PubMed PMID: 21181642.
14. Hoeper MM, Andreas S, Bastian A, Claussen M, Ghofrani HA, Gorenflo M, et al. Pulmonary hypertension due to chronic lung disease: Updated Recommendations of the Cologne Consensus Conference 2011. International journal of cardiology. 2011;154S1:S45-S53. PubMed PMID: 22221973.
15. Randerath WJ, Verbraecken J, Andreas S, Bettega G, Boudewyns A, Hamans E, et al. Non-CPAP therapies in obstructive sleep apnoea. Eur Respir J. 2011;37(5):1000-28. PubMed PMID: 21406515.
16. Raupach T, Merker J, Hasenfuss G, Andreas S, Pipe A. Knowledge gaps about smoking cessation in hospitalized patients and their doctors. Eur J Cardiovasc Prev Rehabil. 2011;18(2):334-41. PubMed PMID: 21450679.
17. Raupach T, Lüthje L, Kögler H, Duwe C, Schweda F, Hasenfuß G, et al. Effects of angiotensin II type 1 receptor blockade on pulmonary and systemic manifestations in an emphysema mouse model. Pulm Pharmac Ther. 2011 24:215-20.
18. Andreas S, Raupach T, Kögler H, Hasenfuß G. Angiotensin receptor blockade in pulmonary emphysema. J Clin Invest. 2012;122(www.jci.org/eletters/view/46215.):229-letter.
19. Andreas S, Rittmeyer A. Epidemiologie und Bedeutung tabakassoziierter Lungenkrankheiten. Der Pneumologe. 2012;9:177-84.
20. Dalhoff K, Abele-Horn M, Andreas S, Bauer T, von Baum H, Deja M, et al. Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. S-3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy. Pneumologie. 2012;66(12):707-65. PubMed PMID: 23225407.
21. Haarmann H, Raupach T, Kitz J, Hinterthaner M, Andreas S. EBUS-TBNA in a case of mediastinal lymphangioma. Journal of bronchology & interventional pulmonology. 2012;19(2):153-5. PubMed PMID: 23207362.
22. Meier M, Andreas S. Mechanisms of cardiovascular co-morbidity in patients with obstructive sleep apnoea syndrome. Pneumologie. 2012;66(11):650-7. PubMed PMID: 23132319.
23. Andreas S, Chenot J-F, Diebold R, Peachey S, Mann K. Effectiveness of varenicline as an aid to smoking cessation in primary care: An observational study Eur Addict Res. 2013;19(1):47-54.
24. Andreas S, Hasenfuss G. Beneficial effects of Angiotensin receptor blockade in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(3):328. PubMed PMID: 23378439.
25. Andreas S, Rittmeyer A, Hinterthaner M, Huber RM. Smoking Cessation in Lung Cancer-Achievable and Effective. Deutsches Arzteblatt international. 2013;110(43):719-24. PubMed PMID: 24222790.
26. Rittmeyer A, Gorbunova V, Vikstrom A, Scherpereel A, Kim JH, Ahn MJ, et al. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). J Thorac Oncol. 2013;8(11):1409-16. Epub 2013/10/01. doi: 10.1097/JTO.0b013e3182a46bcf. PubMed PMID: 24077452.
27. Schuette WH, Groschel A, Sebastian M, Andreas S, Muller T, Schneller F, et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clinical lung cancer. 2013;14(3):215-23. PubMed PMID: 23332288.
28. Wachter R, Luthje L, Klemmstein D, Luers C, Stahrenberg R, Edelmann F, et al. Impact of obstructive sleep apnoea on diastolic function. Eur Respir J. 2013;41:376-83. doi: DOI: 10.1183/09031936.00218211.
29. Andreas S, Batra A, Behr J, Chenot JF, Gillissen A, Hering T, et al. Tabakentwöhnung bei COPD. Pneumologie. 2014;68(4):237-58. PubMed PMID: 24570269.
30. Andreas S, Haarmann H, Klarner S, Hasenfuss G, Raupach T. Increased Sympathetic Nerve Activity in COPD is Associated with Morbidity and Mortality. Lung. 2014;192(2):235-41. PubMed PMID: 24362752.
31. Pepin JL, Cockcroft JR, Midwinter D, Sharma S, Rubin DB, Andreas S. Long-acting bronchodilators and arterial stiffness in patients with COPD: a comparison of fluticasone furoate/vilanterol with tiotropium. Chest. 2014;146(6):1521-30. doi: 10.1378/chest.13-2859. PubMed PMID: 25058845.
32. Reinhardt C, Andreas S. COPD: Tabakentwöhnung als essenzieller Bestandteil der Therapie. Deu Med Wochschr. 2014;139:1240. doi: DOI 10.1055/s-0033-1353985.
33. Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46(1):186-96. doi: 10.1183/09031936.00217614. PubMed PMID: 25837040.
34. Haarmann H, Mohrlang C, Tschiesner U, Rubin DB, Bornemann T, Ruter K, et al. Inhaled beta-agonist does not modify sympathetic activity in patients with COPD. BMC pulmonary medicine. 2015;15:46. doi: 10.1186/s12890-015-0054-7. PubMed PMID: 25924990; PubMed Central PMCID: PMC4460951.
35. Jimenez-Ruiz CA, Andreas S, Lewis KE, Tonnesen P, van Schayck CP, Hajek P, et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. Eur Respir J. 2015;46(1):61-79. doi: 10.1183/09031936.00092614. PubMed PMID: 25882805.
36. Reinhardt C, Andreas S. Tabakentwohnung - was gibt es Neues?- Anwort auf Leserbrief. Dtsch Med Wochenschr. 2015;140(7):528-9. doi: 10.1055/s-0041-101238. PubMed PMID: 25826041.
37. Reinhardt C, Andreas S. Tabakentwohnung - was gibt es Neues? Dtsch Med Wochenschr. 2015;140(3):188-90. doi: 10.1055/s-0041-100074. PubMed PMID: 25658406.
38. Rittmeyer A. Quality of Life in Patients with NSCLC Receiving Maintenance Therapy. Cancers (Basel). 2015;7(2):950-62. Epub 2015/06/04. doi: 10.3390/cancers7020817. PubMed PMID: 26035509; PubMed Central PMCID: PMCPMC4491692.
39. Thomas M, Fischer J, Andreas S, Kortsik C, Grah C, Serke M, et al. Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer. Eur Respir J. 2015;46(1):219-29. doi: 10.1183/09031936.00229014. PubMed PMID: 25792638.
40. Andreas S, Janson C, van den Berge M, Lahousse L. Cardiac impact of inhaled therapy in the largest randomised placebo-controlled trial in COPD history: have we reached the SUMMIT? ERJ Open Res 2016 May 26;2(2) pii: 00055-2016 doi: 101183/2312054100055-2016 eCollection 2016 Apr. 2016;2(2).
41. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837-46. Epub 2016/03/14. doi: 10.1016/S0140-6736(16)00587-0. PubMed PMID: 26970723.
42. Flentje M, Huber RM, Engel-Riedel W, Andreas S, Kollmeier J, Staar S, et al. GILT-A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2016;192(4):216-22. doi: 10.1007/s00066-016-0941-8. PubMed PMID: 26809652.
43. Haarmann H, Folle J, Nguyen XP, Herrmann P, Heusser K, Hasenfuss G, et al. Sympathetic Activation is Associated with Exercise Limitation in COPD. Copd. 2016:1-6. doi: 10.3109/15412555.2015.1136272. PubMed PMID: 26829234.
44. Haarmann H, Folle J, Nguyen XP, Herrmann P, Heusser K, Hasenfuss G, et al. Impact of Non-Invasive Ventilation on Sympathetic Nerve Activity in Chronic Obstructive Pulmonary Disease. Lung. 2016. doi: 10.1007/s00408-016-9965-1. PubMed PMID: 27853876.
45. Haarmann H, Gossler A, Herrmann P, Bonev S, Nguyen XP, Hasenfuss G, et al. Effects of varenicline on sympatho-vagal balance and cue reactivity during smoking withdrawal: a randomised placebo-controlled trial. Tobacco induced diseases. 2016;14:26. doi: 10.1186/s12971-016-0091-x. PubMed PMID: 27507930; PubMed Central PMCID: PMC4977756.
46. Masefield S, Powell P, Jimenez-Ruiz C, Hajek P, Lewis K, Andreas S, et al. Recommendations to improve smoking cessation outcomes from people with lung conditions who smoke. ERJ Open Res 2016 Apr 27;2(2) pii: 00009-2016 doi: 101183/2312054100009-2016 eCollection 2016 Apr. 2016;2(2).
47. Muhlig S, Andreas S, Batra A, Petersen KU, Hoch E, Ruther T. Psychiatrische Komorbiditaten bei tabakbedingten Storungen. Der Nervenarzt. 2016;87(1):46-52. doi: 10.1007/s00115-015-0020-x. PubMed PMID: 26597273.
48. Pujol JL, De Pas T, Rittmeyer A, Vallieres E, Kubisa B, Levchenko E, et al. Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation Study. J Thorac Oncol. 2016;11(12):2208-17. Epub 2016/08/22. doi: 10.1016/j.jtho.2016.08.120. PubMed PMID: 27544054.
49. Randerath W, Verbraecken J, Andreas S, Arzt M, Bloch KE, Brack T, et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J. 2016. doi: 10.1183/13993003.00959-2016. PubMed PMID: 27920092.
50. Rover C, Andreas S, Friede T. Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data. Biometrical journal Biometrische Zeitschrift. 2016;58:170-85. Epub May 12 2015. doi: 10.1002/bimj.201300288. PubMed PMID: 25962834.
51. Glatzer M, Rittmeyer A, Muller J, Opitz I, Papachristofilou A, Psallidas I, et al. Treatment of limited disease small cell lung cancer: the multidisciplinary team. Eur Respir J. 2017;50(2). Epub 2017/08/26. doi: 10.1183/13993003.00422-2017. PubMed PMID: 28838979.
52. Guetz S, Tufman A, von Pawel J, Rittmeyer A, Borgmeier A, Ferre P, et al. Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine - a Phase I trial. Onco Targets Ther. 2017;10:1081-9. Epub 2017/03/07. doi: 10.2147/OTT.S122106. PubMed PMID: 28260922; PubMed Central PMCID: PMCPMC5328303.
53. Haarmann H, Folle J, Nguyen XP, Herrmann P, Heusser K, Hasenfuss G, et al. Impact of Non-Invasive Ventilation on Sympathetic Nerve Activity in Chronic Obstructive Pulmonary Disease. Lung. 2017;195(1):69-75. doi: 10.1007/s00408-016-9965-1. PubMed PMID: 27853876.
54. Heigener DF, Hoeffken G, Wuerflein D, Feurer M, Rittmeyer A, Huber RM, et al. [Chemotherapy in the Elderly with Non-Small Cell Lung Cancer: A Non-Interventional, Prospective, Multicentric Observational Study]. Dtsch Med Wochenschr. 2017;142(4):e21-e7. Epub 2017/02/25. doi: 10.1055/s-0042-121785. PubMed PMID: 28235221.
55. Hirsch FR, Govindan R, Zvirbule Z, Braiteh F, Rittmeyer A, Belda-Iniesta C, et al. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. Clinical lung cancer. 2017;18(1):43-9. Epub 2016/07/28. doi: 10.1016/j.cllc.2016.05.011. PubMed PMID: 27461773.
56. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18(1):139. doi: 10.1186/s12931-017-0621-y. PubMed PMID: 28709421; PubMed Central PMCID: PMC5512739.
57. Magnussen H, Arzt M, Andreas S, Plate T, Ribera A, Seoane B, et al. Aclidinium bromide improves symptoms and sleep quality in COPD: a pilot study. Eur Respir J. 2017;49(6). doi: 10.1183/13993003.00485-2017. PubMed PMID: 28642315.
58. Randerath W, Verbraecken J, Andreas S, Arzt M, Bloch KE, Brack T, et al. Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep. Eur Respir J. 2017;49(1). doi: 10.1183/13993003.00959-2016. PubMed PMID: 27920092.
59. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-65. Epub 2016/12/17. doi: 10.1016/S0140-6736(16)32517-X. PubMed PMID: 27979383; PubMed Central PMCID: PMCPMC6886121.
60. Vansteenkiste J, Wauters E, Park K, Rittmeyer A, Sandler A, Spira A. Prospects and progress of atezolizumab in non-small cell lung cancer. Expert Opin Biol Ther. 2017;17(6):781-9. Epub 2017/03/25. doi: 10.1080/14712598.2017.1309389. PubMed PMID: 28335643.
61. Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med 2018 Apr;137:14-22 doi: 101016/jrmed201802011 Epub 2018 Feb 19. 2018;137:14-22.
62. Andreas S. The association of cardiovascular autonomic dysfunction and the prediction of COPD can be explained by neurohumoral activation. Eur Respir J. 2018;51(6). doi: 10.1183/13993003.00737-2018. PubMed PMID: 29880542.
63. Andreas S, Alt-Epping B. Advance care planning in severe COPD: it is time to engage with the future. ERJ Open Res. 2018;4:pii: 00009-2018.
64. Andreas S, Bothner U, Trampisch M, Haensel M, Buhl R, Alter P. Effect of long-acting beta2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. Pulmonary pharmacology & therapeutics. 2018;52:1-6. PubMed PMID: 30077810.
65. Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, et al. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Lung cancer. 2018. doi: 10.1016/j.lungcan.2018.06.007. PubMed PMID: 29961557.
66. Andreas S, Jany B, Hering T, Rustler C, Grah C, Pfeifer M. OPS „Tabakentwöhnung“ im DRG-System – eine lohnende Perspektive für Patienten und Klinik. Pneumologie 2018 Feb;72(2):103-105 doi: 101055/s-0044-101117 Epub 2018 Feb 20. 2018;72(2):103-5.
67. Andreas S, Reinhardt C. Increased Arterial Stiffness Might Be Caused by Sympathetic Activation. Chest. 2018;153(153):569.
68. Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, et al. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer. Clinical lung cancer. 2018;19(5):441-9 e4. Epub 2018/07/19. doi: 10.1016/j.cllc.2018.05.011. PubMed PMID: 30017645.
69. Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, et al. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung cancer. 2018;124:310-6. PubMed PMID: 30119925.
70. Claret L, Jin JY, Ferte C, Winter H, Girish S, Stroh M, et al. A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. Clin Cancer Res. 2018;24(14):3292-8. Epub 2018/04/25. doi: 10.1158/1078-0432.CCR-17-3662. PubMed PMID: 29685883.
71. Dalhoff K, Abele-Horn M, Andreas S, Deja M, Ewig S, Gastmeier P, et al. [Epidemiology, Diagnosis and Treatment of Adult Patients with Nosocomial Pneumonia - Update 2017 - S3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy, the German Radiological Society and the Society for Virology]. Pneumologie 2018 Jan;72(1):15-63 doi: 101055/s-0043-121734 Epub 2018 Jan 16. 2018;72(1):15-63.
72. Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, et al. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(8):1156-70. Epub 2018/05/20. doi: 10.1016/j.jtho.2018.04.039. PubMed PMID: 29777823.
73. Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441-8. Epub 2018/08/08. doi: 10.1038/s41591-018-0134-3. PubMed PMID: 30082870.
74. Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland A, Han JY, et al. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. J Thorac Oncol. 2018;13(12):1906-18. Epub 2018/09/16. doi: 10.1016/j.jtho.2018.08.2027. PubMed PMID: 30217492.
75. Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, et al. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer. Medical oncology. 2018;35(7):106. doi: 10.1007/s12032-018-1169-5. PubMed PMID: 29905882.
76. Alter P, Mayerhofer BA, Kahnert K, Watz H, Waschki B, Andreas S, et al. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort. Int J Chron Obstruct Pulmon Dis. 2019;14:2163-72. PubMed PMID: 31571852.
77. Andreas S, Rover C, Heinz J, Straube S, Watz H, Friede T. Decline of COPD exacerbations in clinical trials over two decades - a systematic review and meta-regression. Respir Res. 2019;20(1):186. PubMed PMID: 31420040.
78. Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, et al. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung cancer. 2019;128:105-12. Epub 2019/01/16. doi: 10.1016/j.lungcan.2018.12.017. PubMed PMID: 30642441.
79. Haarmann H, Koch J, Bonsch N, Mende M, Werhahn SM, Luers C, et al. Morbidity and mortality in patients with cardiovascular risk factors and obstructive sleep apnoea: results from the DIAST-CHF cohort. Respir Med. 2019;154:127-32. PubMed PMID: 31252205.
80. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019;20(1):59. PubMed PMID: 30876420.
81. Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, et al. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers. Clin Cancer Res. 2019;25(1):64-72. Epub 2018/09/13. doi: 10.1158/1078-0432.CCR-18-1590. PubMed PMID: 30206164.
82. Radovic M, Kanesvaran R, Rittmeyer A, Fruh M, Minervini F, Glatzer M, et al. Multidisciplinary treatment of lung cancer in older patients: A review. J Geriatr Oncol. 2019;10(3):405-10. Epub 2018/10/08. doi: 10.1016/j.jgo.2018.09.005. PubMed PMID: 30292418.
83. Schiwitza A, Schildhaus HU, Zwerger B, Ruschoff J, Reinhardt C, Leha A, et al. Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Immunotherapy. 2019;11(9):769-82. PubMed PMID: 31120392.
84. Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, et al. Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab. Oncology letters. 2019;17(6):4891-900. PubMed PMID: 31186697.
85. von Pawel J, Bordoni R, Satouchi M, Fehrenbacher L, Cobo M, Han JY, et al. Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. Eur J Cancer. 2019;107:124-32. Epub 2018/12/19. doi: 10.1016/j.ejca.2018.11.020. PubMed PMID: 30562710.
86. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924-37. Epub 2019/05/28. doi: 10.1016/S1470-2045(19)30167-6. PubMed PMID: 31122901.
87. Wildung M, Esser TU, Grausam KB, Wiedwald C, Volceanov-Hahn L, Riedel D, et al. Transcription factor TAp73 and microRNA-449 complement each other to support multiciliogenesis. Cell death and differentiation. 2019;26(12):2740-57. PubMed PMID: 31068677.
88. Andreas S, Bothner U, de la Hoz A, Kloer I, Trampisch M, Alter P. A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1955-65. Epub 2020/08/28. doi: 10.2147/COPD.S246353. PubMed PMID: 32848381; PubMed Central PMCID: PMCPMC7428408.
89. Andreas S, Bothner U, de la Hoz A, Kloer I, Trampisch M, Alter P. No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1945-53. Epub 2020/08/28. doi: 10.2147/COPD.S246350. PubMed PMID: 32848380; PubMed Central PMCID: PMCPMC7429402.
90. Andreas S, McGarvey L, Bothner U, Trampisch M, de la Hoz A, Flezar M, et al. Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:1935-44. Epub 2020/08/28. doi: 10.2147/COPD.S246348. PubMed PMID: 32848379; PubMed Central PMCID: PMCPMC7428407.
91. Andreas S, Taube C. Inhaled therapy reduces COPD mortality. ERJ Open Res. 2020;6(4). Epub 2020/12/10. doi: 10.1183/23120541.00634-2020. PubMed PMID: 33294425; PubMed Central PMCID: PMCPMC7701338 of the study; and grants and personal fees from Boehringer Ingelheim, grants from Pfizer, and personal fees from Novartis, AstraZeneca, GSK, Chiesi and Merini, outside the submitted work. Conflict of interest: C. Taube has nothing to disclose.
92. Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020;56(2). Epub 2020/05/10. doi: 10.1183/13993003.02279-2019. PubMed PMID: 32381492.
93. Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, et al. Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV. Clin Med Insights Oncol. 2020;14:1179554920951358. Epub 2020/09/05. doi: 10.1177/1179554920951358. PubMed PMID: 32884390; PubMed Central PMCID: PMCPMC7440727.
94. Chalabi M, Cardona A, Nagarkar DR, Dhawahir Scala A, Gandara DR, Rittmeyer A, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020;31(4):525-31. Epub 2020/03/03. doi: 10.1016/j.annonc.2020.01.006. PubMed PMID: 32115349.
95. Giese D, Blau J, Knuppel W, Neumann-Schiebener A, Gunther A, Reinhardt C, et al. Vertrag zur prolongierten Beatmungsentwohnung der AOK Hessen-Methodik und erste Erfahrungen. Dtsch Med Wochenschr. 2020;145(19):e108-e15. Epub 2020/09/10. doi: 10.1055/a-1207-7731. PubMed PMID: 32906157; PubMed Central PMCID: PMCPMC7515656.
96. Haidl P, Jany B, Geiseler J, Andreas S, Arzt M, Dreher M, et al. [Guideline for Long-Term Oxygen Therapy - S2k-Guideline Published by the German Respiratory Society]. Pneumologie. 2020;74(12):813-41. Epub 2020/12/09. doi: 10.1055/a-1252-1492. PubMed PMID: 33291162.
97. Iseli T, Berghmans T, Glatzer M, Rittmeyer A, Massard G, Durieux V, et al. Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy. ERJ Open Res. 2020;6(3). Epub 2020/09/24. doi: 10.1183/23120541.00010-2020. PubMed PMID: 32963993; PubMed Central PMCID: PMCPMC7487347 Berghmans has nothing to disclose. Conflict of interest: M. Glatzer has nothing to disclose. Conflict of interest: A. Rittmeyer reports grants from AbbVie, AstraZeneca, BMS, Eli Lilly, Boehringer Ingelheim, MSD, Pfizer and Roche, outside the submitted work. Conflict of interest: G. Massard has nothing to disclose. Conflict of interest: V. Durieux has nothing to disclose. Conflict of interest: T. Buchsbaum has nothing to disclose. Conflict of interest: P.M. Putora has nothing to disclose.
98. Omlor AJ, Trudzinski FC, Alqudrah M, Seiler F, Biertz F, Vogelmeier CF, et al. Time-updated resting heart rate predicts mortality in patients with COPD. Clin Res Cardiol. 2020;109(6):776-86. Epub 2019/11/18. doi: 10.1007/s00392-019-01572-1. PubMed PMID: 31734762.
99. Overbeck TR, Cron DA, Schmitz K, Rittmeyer A, Korber W, Hugo S, et al. Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Transl Lung Cancer Res. 2020;9(3):603-16. Epub 2020/07/18. doi: 10.21037/tlcr-19-339. PubMed PMID: 32676323; PubMed Central PMCID: PMCPMC7354108.
100. Andreas S, Pankow W. [Smoking cessation - achievable and effective]. Dtsch Med Wochenschr. 2021;146(11):748-51. Epub 2021/06/02. doi: 10.1055/a-1259-8353. PubMed PMID: 34062591.
101. Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476-86. Epub 2021/04/03. doi: 10.1016/S2213-2600(20)30554-3. PubMed PMID: 33798455.
102. Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, et al. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Transl Lung Cancer Res. 2021;10(7):3093-105. Epub 2021/08/26. doi: 10.21037/tlcr-21-197. PubMed PMID: 34430350; PubMed Central PMCID: PMCPMC8350088.
103. Gandara D, Reck M, Moro-Sibilot D, Mazieres J, Gadgeel S, Morris S, et al. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. J Immunother Cancer. 2021;9(3). Epub 2021/03/20. doi: 10.1136/jitc-2020-001882. PubMed PMID: 33737340; PubMed Central PMCID: PMCPMC7978260.
104. Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, et al. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung cancer. 2021;152:174-84. Epub 2020/12/29. doi: 10.1016/j.lungcan.2020.10.012. PubMed PMID: 33358484.
105. Illini O, Hochmair MJ, Fabikan H, Weinlinger C, Tufman A, Swalduz A, et al. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Ther Adv Med Oncol. 2021;13:17588359211019675. Epub 2021/06/29. doi: 10.1177/17588359211019675. PubMed PMID: 34178121; PubMed Central PMCID: PMCPMC8202258.
106. Klooster K, Valipour A, Marquette CH, Boutros J, Mal H, Marceau A, et al. Endobronchial Coil System versus Standard-of-Care Medical Management in the Treatment of Subjects with Severe Emphysema. Respiration. 2021;100(8):804-10. Epub 2021/05/10. doi: 10.1159/000515744. PubMed PMID: 33965944; PubMed Central PMCID: PMCPMC8491498.
107. Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis DL, et al. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials. J Thorac Oncol. 2021;16(1):140-50. Epub 2020/11/10. doi: 10.1016/j.jtho.2020.09.022. PubMed PMID: 33166718.
108. Pankow W, Andreas S, Rupp A, Pfeifer M. [Smoking Cessation with E-Cigarettes? - Ad Hoc Statement of the German Respiratory Society (DGP)]. Pneumologie. 2021;75(1):31-2. Epub 2020/12/08. doi: 10.1055/a-1323-6045. PubMed PMID: 33285598.
109. Raspe M, Bals R, Hering T, Pankow W, Rupp A, Rustler C, et al. [COVID-19 and Smoking - A Position Paper by the DGP Taskforce for Smoking Cessation]. Pneumologie. 2021;75(11):846-55. Epub 2021/05/28. doi: 10.1055/a-1503-1744. PubMed PMID: 34041722.
110. Rittmeyer A, Schiwitza A, Sahovic L, Eul B, Andreas S. Update on recent key publications in lung oncology: picking up speed. Eur Respir Rev. 2021;30(161). Epub 2021/07/16. doi: 10.1183/16000617.0300-2020. PubMed PMID: 34261741; PubMed Central PMCID: PMCPMC9488240 Ingelheim, AstraZeneca, MSD, Pfizer, AbbVie, Novartis and Roche, outside the submitted work. Conflict of interest: A. Schiwitza has nothing to disclose. Conflict of interest: L. Sahovic has nothing to disclose. Conflict of interest: B. Eul has nothing to disclose. Conflict of interest: S. Andreas reports grants and personal fees from Boehringer Ingelheim, personal fees from Novartis, AstraZeneca, GSK, Chiesi and Merini, and grants from Pfizer, outside the submitted work.
111. Tufman A, Neumann J, Manapov F, Sellmer L, Jung A, Kauffmann-Guerrero D, et al. Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT). Lung cancer. 2021;160:17-27. Epub 2021/08/10. doi: 10.1016/j.lungcan.2021.07.008. PubMed PMID: 34371299.
112. Alter P, Kahnert K, Trudzinski FC, Bals R, Watz H, Speicher T, et al. Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET. Int J Chron Obstruct Pulmon Dis. 2022;17:1703-13. Epub 2022/08/09. doi: 10.2147/COPD.S364812. PubMed PMID: 35936574; PubMed Central PMCID: PMCPMC9346297.
113. Alter P, Lucke T, Watz H, Andreas S, Kahnert K, Trudzinski FC, et al. Cardiovascular predictors of mortality and exacerbations in patients with COPD. Sci Rep. 2022;12(1):21882. Epub 2022/12/20. doi: 10.1038/s41598-022-25938-0. PubMed PMID: 36536050; PubMed Central PMCID: PMCPMC9763357.
114. Andreas S, Rover C, Heinz J, Taube C, Friede T. COPD mortality and exacerbations in the placebo group of clinical trials over two decades: a systematic review and meta-regression. ERJ Open Res. 2022;8(1). Epub 2022/03/11. doi: 10.1183/23120541.00261-2021. PubMed PMID: 35265703; PubMed Central PMCID: PMCPMC8899495 during the conduct of the study; and grants and personal fees from Boehringer Ingelheim, grants from Pfizer, and personal fees from Novartis, AstraZeneca, GSK, Chiesi and Merini, outside the submitted work. Conflict of interest: C. Rover has nothing to disclose. Conflict of interest: J. Heinz has nothing to disclose. Conflict of interest: C. Taube has nothing to disclose. Conflict of interest: T. Friede reports consultancy fees from Novartis, Bayer, Janssen, Roche, Boehringer Ingelheim, Daiichi-Sankyo, Galapagos, Penumbra, Parexel, Vifor, BiosenseWebster, CSL Behring, Fresenius Kabi, Coherex Medical, LivaNova and Minoryx, outside the submitted work.
115. Andreas S, Testa M, Boyer L, Brusselle G, Janssens W, Kerwin E, et al. Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial. Lancet Respir Med. 2022;10(5):435-46. Epub 2022/01/14. doi: 10.1016/S2213-2600(21)00502-6. PubMed PMID: 35026180.
116. Batra A, Kiefer F, Andreas S, Gohlke H, Klein M, Kotz D, et al. S3 Guideline "Smoking and Tobacco Dependence: Screening, Diagnosis, and Treatment" - Short Version. Eur Addict Res. 2022;28(5):382-400. Epub 2022/06/28. doi: 10.1159/000525265. PubMed PMID: 35760048.
117. Gadgeel S, Hirsch FR, Kerr K, Barlesi F, Park K, Rittmeyer A, et al. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. Clinical lung cancer. 2022;23(1):21-33. Epub 2021/07/07. doi: 10.1016/j.cllc.2021.05.007. PubMed PMID: 34226144.
118. Guhlich M, Maag TE, Droge LH, El Shafie RA, Hille A, Donath S, et al. Symptom relief, prognostic factors, and outcome in patients receiving urgent radiation therapy for superior vena cava syndrome : A single-center retrospective analysis of 21 years' practice. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2022;198(12):1072-81. Epub 2022/05/14. doi: 10.1007/s00066-022-01952-z. PubMed PMID: 35552767; PubMed Central PMCID: PMCPMC9700593.
119. Kahnert K, Andreas S, Kellerer C, Lutter JI, Lucke T, Yildirim O, et al. Reduced decline of lung diffusing capacity in COPD patients with diabetes and metformin treatment. Sci Rep. 2022;12(1):1435. Epub 2022/01/28. doi: 10.1038/s41598-022-05276-x. PubMed PMID: 35082306; PubMed Central PMCID: PMCPMC8792053.
120. Lenga P, Grah C, Ruwwe-Glosenkamp C, Saccomanno J, Ruckert J, Eggeling S, et al. Endoscopic Lung Volume Reduction with One-Way Valves in Patients with Severe Chronic Obstructive Pulmonary Disease with Hypercapnia. Respiration. 2022;101(9):823-32. Epub 2022/07/06. doi: 10.1159/000524996. PubMed PMID: 35785772.
121. Reinhardt C, Harden M, Herrmann-Lingen C, Rittmeyer A, Andreas S. Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients. BMC pulmonary medicine. 2022;22(1):252. Epub 2022/06/28. doi: 10.1186/s12890-022-02048-1. PubMed PMID: 35761222; PubMed Central PMCID: PMCPMC9235273.
122. Ammous O, Andreas S, Friede T, Kampo R, Schwarz S, Wollsching-Strobel M, et al. Adherence enhancing interventions for pharmacological and oxygen therapy in patients with COPD: protocol for a systematic review and component network meta-analyses. Syst Rev. 2023;12(1):159. Epub 2023/09/09. doi: 10.1186/s13643-023-02326-x. PubMed PMID: 37684691; PubMed Central PMCID: PMCPMC10486002.
123. Andreas S, Kotz D, Batra A, Hellmann A, Muhlig S, Nowak D, et al. [Smoking Cessation in Patients with COPD]. Pneumologie. 2023;77(4):206-19. Epub 2023/03/24. doi: 10.1055/a-2020-4284. PubMed PMID: 36958341.
124. Felip E, Altorki N, Zhou C, Vallieres E, Martinez-Marti A, Rittmeyer A, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023;34(10):907-19. Epub 2023/07/20. doi: 10.1016/j.annonc.2023.07.001. PubMed PMID: 37467930.
125. Lee SM, Schulz C, Prabhash K, Kowalski D, Szczesna A, Han B, et al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study. Lancet. 2023;402(10400):451-63. Epub 2023/07/10. doi: 10.1016/S0140-6736(23)00774-2. PubMed PMID: 37423228.
126. Mhatre SK, Machado RJM, Ton TGN, Trinh H, Mazieres J, Rittmeyer A, et al. Real-World Progression-Free Survival as an Endpoint in Lung Cancer: Replicating Atezolizumab and Docetaxel Arms of the OAK Trial Using Real-World Data. Clin Pharmacol Ther. 2023;114(6):1313-22. Epub 2023/09/12. doi: 10.1002/cpt.3045. PubMed PMID: 37696652.
127. Overbeck TR, Reiffert A, Schmitz K, Rittmeyer A, Korber W, Hugo S, et al. NTRK Gene Fusions in Non-Small-Cell Lung Cancer: Real-World Screening Data of 1068 Unselected Patients. Cancers (Basel). 2023;15(11). Epub 2023/06/10. doi: 10.3390/cancers15112966. PubMed PMID: 37296928; PubMed Central PMCID: PMCPMC10252111.
128. Raspe M, Bals R, Bolukbas S, Faber G, Krabbe B, Landmesser U, et al. [Smoking cessation in hospitalised patients - Initiate among inpatients, continue when outpatients - A Position Paper by the German Respiratory Society (DGP) Taskforce for Smoking Cessation]. Pneumologie. 2023;77(6):341-9. Epub 2023/05/15. doi: 10.1055/a-2071-8900. PubMed PMID: 37186277.
129. Sgarbossa T, Lenga P, Stanzel F, Holland A, Grah C, Gesierich W, et al. Assessment of efficacy and safety of endoscopic lung volume reduction with one-way valves in patients with a very low FEV(1). ERJ Open Res. 2023;9(4). Epub 2023/08/23. doi: 10.1183/23120541.00190-2023. PubMed PMID: 37609599; PubMed Central PMCID: PMCPMC10440652 DFG, outside the submitted work; consulting fees from Acceleron, AstraZeneca and Sanofi Genzyme, outside the submitted work; payment for expert testimony for Nanovation, outside the submitted work; support for attending meetings and/or travel from Boehringer Ingelheim and Sanofi Genzyme, outside the submitted work. Conflict of interest: M. Witzenrath reports grants or contracts from Deutsche Forschungsgemeinschaft, Bundesministerium fur Bildung und Forschung, Deutsche Gesellschaft fur Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kroner Fresenius Stiftung, Capnetz Stiftung, Bayer Health Care, Biotest and Pantherna, outside the submitted work; consulting fees from Insmed, Pantherna, Pherecydes, Aptarion, GlaxoSmithKline, Inflarx and Biotest, outside the submitted work; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Insmed, Chiesi, Novartis, Teva, Actelion, Boehringer Ingelheim, GlaxoSmithKline, Biotest and Bayer Health Care, outside the submitted work; patents issued EPO 12181535.1 (IL-27 for modulation of immune response in acute lung injury), WO/2010/094491 (Means for inhibiting the expression of Ang-2), DE 102020116249.9 (Camostat/Niclosamide cotreatment in SARS-CoV-2 infected human lung cells) and PCT/EP2021/075627 (New medical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators), outside the submitted work. Conflict of interest: A. Holland reports being a board member of Lungenemphysemregister e.V., outside the submitted work. Conflict of interest: W. Gesierich reports lectures fees from PulmonX GmbH, outside the submitted work. Conflict of interest: R-H. Hubner reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pulmonx, Olympus and AstraZeneca, outside the submitted work; participation on a data safety monitoring board or advisory board for Bento Study (sponsor: IHF GmbH - Institut fur Herzinfarktforschung), outside the submitted work; leadership or fiduciary role in other board, society, committee or advocacy group for Head of Lungenemphysem Register e.V., outside the submitted work. Conflict of interest: The remaining authors have nothing to disclose.
130. Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Luders H, et al. Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (>/=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer. J Thorac Oncol. 2024;19(5):803-17. Epub 2023/12/15. doi: 10.1016/j.jtho.2023.12.015. PubMed PMID: 38096950.
131. Blum TG, Vogel-Claussen J, Andreas S, Bauer TT, Barkhausen J, Harth V, et al. [Statement paper on the implementation of a national organized program in Germany for the early detection of lung cancer in risk populations using low-dose CT screening including management of screening findings]. Pneumologie. 2024;78(1):15-34. Epub 2023/10/11. doi: 10.1055/a-2175-4580. PubMed PMID: 37816379.
132. Franzen K, Pankow W, Andreas S. [The e-cigarette - means of smoking cessation?]. Laryngorhinootologie. 2024;103(2):107-12. Epub 2023/11/22. doi: 10.1055/a-2194-5666. PubMed PMID: 37989216.
133. Hoffmann H, Kaaks R, Andreas S, Bauer TT, Barkhausen J, Harth V, et al. [Statement Paper on the Implementation of a National Organized Program in Germany for the Early Detection of Lung Cancer in Risk Populations Using Low-dose CT Screening Including Management of Screening Findings]. Zentralbl Chir. 2024;149(1):96-115. Epub 2023/10/11. doi: 10.1055/a-2178-5907. PubMed PMID: 37816386.
134. Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, et al. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2024;42(3):324-35. Epub 2023/11/17. doi: 10.1200/JCO.23.01363. PubMed PMID: 37976444; PubMed Central PMCID: PMCPMC10824371 manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
135. Vogel-Claussen J, Blum TG, Andreas S, Bauer TT, Barkhausen J, Harth V, et al. [Statement paper on the implementation of a national organized program in Germany for the early detection of lung cancer in risk populations using low-dose CT screening including management of screening findings]. Rofo. 2024;196(2):134-53. Epub 2023/10/11. doi: 10.1055/a-2178-2846. PubMed PMID: 37816377.
